Journal of the Peripheral Nervous System最新文献_第3页

Broadening the Clinical Spectrum of Axonal Hereditary Neuropathies: A Comparative Case Study on DNAJB2- and HINT1-Related Disease 拓宽轴突遗传性神经病的临床谱：DNAJB2-和hint1相关疾病的比较病例研究

IF 3.2 3区医学 Q1 CLINICAL NEUROLOGY

Journal of the Peripheral Nervous System

Pub Date : 2026-01-19 DOI: 10.1111/jns.70100

Bogdan Bjelica, Corinna Hendrich, Sandra von Hardenberg, Milica Vukojevic, Sonja Körner, Thomas Gschwendtberger, Aiden Haghikia, Stojan Peric, Susanne Petri

Background and Aims

Differentiating hereditary axonal polyneuropathies caused by distinct gene variants remains a clinical challenge. This comparative case study of DNAJB2- and HINT1-related neuropathies aimed to broaden the phenotypic spectrum associated with these genes and to explore non-motor symptoms and quality of life (QoL) in affected individuals.

Methods

Six patients carrying two novel DNAJB2 variants and six age-matched patients with HINT1 variants underwent detailed clinical and electrophysiological characterization. Motor function was assessed longitudinally using the Medical Research Council (MRC) scale. Non-motor symptoms (neuropathic pain, autonomic dysfunction, depression, fatigue, restless legs syndrome) and QoL were evaluated with patient-reported outcomes and compared to four healthy controls (HC).

Results

Both patient groups exhibited a CMT2 phenotype. Nerve conduction studies revealed a length-dependent axonal predominantly motor but not pure motor neuropathy in most of the patients. Disease onset tended to occur later in patients with DNAJB2 variants, who yet developed more severe neuropathy. The spectrum of additional clinical features differed between the two groups. All patients with DNAJB2 variants fulfilled criteria for depression, compared with one with a HINT1 variant. Significant fatigue was present in the majority of both groups, while restless legs syndrome was observed in four patients with a DNAJB2 variant but in none with a HINT1. QoL was significantly reduced in DNAJB2 versus HC, with no difference in QoL between patients with DNAJB2 and HINT1 variants.

Interpretation

This study expands the clinical spectrum of DNAJB2- and HINT1-related neuropathies, highlighting distinct non-motor features and their impact on QoL, and providing the first direct comparison of these two rare axonal disorders.

背景和目的：鉴别由不同基因变异引起的遗传性轴突多发性神经病仍然是一个临床挑战。这项DNAJB2-和hint1相关神经病的比较病例研究旨在拓宽与这些基因相关的表型谱，并探索受影响个体的非运动症状和生活质量（QoL）。方法：6例携带两种新型DNAJB2变异的患者和6例年龄匹配的HINT1变异患者进行了详细的临床和电生理表征。运动功能采用医学研究委员会（MRC）量表进行纵向评估。非运动症状（神经性疼痛、自主神经功能障碍、抑郁、疲劳、不宁腿综合征）和生活质量用患者报告的结果进行评估，并与4名健康对照（HC）进行比较。结果：两组患者均表现出CMT2表型。神经传导研究显示，在大多数患者中，长度依赖的轴突主要是运动神经病，而不是纯粹的运动神经病。DNAJB2变异体患者往往发病较晚，但会发展为更严重的神经病变。两组之间的其他临床特征谱存在差异。所有的DNAJB2变异患者都符合抑郁症的标准，而只有一名HINT1变异患者符合。两组中的大多数患者都出现了明显的疲劳，而在4名DNAJB2变异患者中观察到不宁腿综合征，但没有人患有HINT1。与HC相比，DNAJB2患者的生活质量显著降低，DNAJB2和HINT1变体患者的生活质量没有差异。解释：本研究扩展了DNAJB2-和hint1相关神经病的临床谱，突出了不同的非运动特征及其对生活质量的影响，并首次直接比较了这两种罕见的轴突疾病。

{"title":"Broadening the Clinical Spectrum of Axonal Hereditary Neuropathies: A Comparative Case Study on DNAJB2- and HINT1-Related Disease","authors":"Bogdan Bjelica, Corinna Hendrich, Sandra von Hardenberg, Milica Vukojevic, Sonja Körner, Thomas Gschwendtberger, Aiden Haghikia, Stojan Peric, Susanne Petri","doi":"10.1111/jns.70100","DOIUrl":"10.1111/jns.70100","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Differentiating hereditary axonal polyneuropathies caused by distinct gene variants remains a clinical challenge. This comparative case study of <i>DNAJB2</i>- and <i>HINT1</i>-related neuropathies aimed to broaden the phenotypic spectrum associated with these genes and to explore non-motor symptoms and quality of life (QoL) in affected individuals.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Six patients carrying two novel <i>DNAJB2</i> variants and six age-matched patients with <i>HINT1</i> variants underwent detailed clinical and electrophysiological characterization. Motor function was assessed longitudinally using the Medical Research Council (MRC) scale. Non-motor symptoms (neuropathic pain, autonomic dysfunction, depression, fatigue, restless legs syndrome) and QoL were evaluated with patient-reported outcomes and compared to four healthy controls (HC).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Both patient groups exhibited a CMT2 phenotype. Nerve conduction studies revealed a length-dependent axonal predominantly motor but not pure motor neuropathy in most of the patients. Disease onset tended to occur later in patients with <i>DNAJB2</i> variants, who yet developed more severe neuropathy. The spectrum of additional clinical features differed between the two groups. All patients with <i>DNAJB2</i> variants fulfilled criteria for depression, compared with one with a <i>HINT1</i> variant. Significant fatigue was present in the majority of both groups, while restless legs syndrome was observed in four patients with a <i>DNAJB2</i> variant but in none with a <i>HINT1</i>. QoL was significantly reduced in <i>DNAJB2</i> versus HC, with no difference in QoL between patients with <i>DNAJB2</i> and <i>HINT1</i> variants.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>This study expands the clinical spectrum of <i>DNAJB2</i>- and <i>HINT1</i>-related neuropathies, highlighting distinct non-motor features and their impact on QoL, and providing the first direct comparison of these two rare axonal disorders.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"31 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-01-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12813656/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145998084","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Persistent Sciatic Artery as a Rare Cause of Sciatic Neuropathy: A Case Report 持续性坐骨动脉是坐骨神经病变的罕见病因：1例报告。

IF 3.2 3区医学 Q1 CLINICAL NEUROLOGY

Journal of the Peripheral Nervous System

Pub Date : 2026-01-18 DOI: 10.1111/jns.70102

Octavian Vatavu, Sara Ciletti, Niccolò Innocenti, Vittoria Maria Luisa Cojazzi, Grazia Devigili, Marco Moscatelli, Vittoria Nazzi

Background

Persistent Sciatic Artery (PSA) is a rare congenital vascular anomaly, affecting 0.05% of the population. It arises from the failure of regression of the embryonic sciatic artery, which normally recedes as the superficial femoral artery (SFA) becomes dominant in lower limb perfusion. In cases of persistence, the sciatic artery remains as a continuation of the internal iliac artery. PSA is classified based on its persistence and anatomical relationship with the SFA and is associated with complications such as limb ischemia, aneurysmal degeneration, and thromboembolism, which may clinically manifest as gluteal pain, claudication, or acute ischemia.

Results

We describe the case of a 50-year-old woman with a longstanding history of left-sided sciatica and paresthesia, refractory to medical therapy. Neurological examination revealed a positive Tinel's sign along the course of the sciatic nerve, and imaging studies confirmed a Pillet-Gauffre type 1 PSA, in close anatomical contiguity with the nerve. Angio-CT excluded associated aneurysmal changes. In the absence of motor involvement, a conservative management strategy was adopted, with referral for vascular surgical evaluation.

Interpretation

Sciatic nerve compression secondary to PSA is exceedingly rare, with most documented cases attributed to aneurysmal dilation exerting mass effect. Electrophysiological features of PSA-related sciatic neuropathy are unreported. This case emphasizes the possibility of including PSA within the differential diagnosis of sciatic pain, particularly when conventional aetiologies have been excluded. Recognition of this vascular anomaly is essential for accurate diagnosis and appropriate management, as surgical intervention does not uniformly result in symptoms resolution.

背景：持续性坐骨动脉（PSA）是一种罕见的先天性血管异常，约占总人口的0.05%。它是由胚胎坐骨动脉消退失败引起的，当股浅动脉（SFA）在下肢灌注中占主导地位时，它通常会消退。在持续性病例中，坐骨动脉作为髂内动脉的延续。PSA根据其持续性和与SFA的解剖关系进行分类，并与肢体缺血、动脉瘤变性和血栓栓塞等并发症相关，这些并发症在临床上可能表现为臀痛、跛行或急性缺血。结果：我们描述的情况下，一个50岁的妇女与长期历史的左侧坐骨神经痛和感觉异常，难治性药物治疗。神经学检查显示沿坐骨神经行tiel征阳性，影像学检查证实与神经解剖接近的Pillet-Gauffre 1型PSA。血管ct排除相关的动脉瘤改变。在没有运动受累的情况下，采用保守治疗策略，并转介血管手术评估。结论：继发于PSA的坐骨神经压迫是非常罕见的，大多数记录的病例归因于动脉瘤扩张产生肿块效应。psa相关坐骨神经病变的电生理特征未见报道。本病例强调了将PSA纳入坐骨痛鉴别诊断的可能性，特别是在排除了常规病因的情况下。这种血管异常的识别对于准确的诊断和适当的处理是必不可少的，因为手术干预并不总是导致症状的解决。

{"title":"Persistent Sciatic Artery as a Rare Cause of Sciatic Neuropathy: A Case Report","authors":"Octavian Vatavu, Sara Ciletti, Niccolò Innocenti, Vittoria Maria Luisa Cojazzi, Grazia Devigili, Marco Moscatelli, Vittoria Nazzi","doi":"10.1111/jns.70102","DOIUrl":"10.1111/jns.70102","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Persistent Sciatic Artery (PSA) is a rare congenital vascular anomaly, affecting 0.05% of the population. It arises from the failure of regression of the embryonic sciatic artery, which normally recedes as the superficial femoral artery (SFA) becomes dominant in lower limb perfusion. In cases of persistence, the sciatic artery remains as a continuation of the internal iliac artery. PSA is classified based on its persistence and anatomical relationship with the SFA and is associated with complications such as limb ischemia, aneurysmal degeneration, and thromboembolism, which may clinically manifest as gluteal pain, claudication, or acute ischemia.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>We describe the case of a 50-year-old woman with a longstanding history of left-sided sciatica and paresthesia, refractory to medical therapy. Neurological examination revealed a positive Tinel's sign along the course of the sciatic nerve, and imaging studies confirmed a Pillet-Gauffre type 1 PSA, in close anatomical contiguity with the nerve. Angio-CT excluded associated aneurysmal changes. In the absence of motor involvement, a conservative management strategy was adopted, with referral for vascular surgical evaluation.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>Sciatic nerve compression secondary to PSA is exceedingly rare, with most documented cases attributed to aneurysmal dilation exerting mass effect. Electrophysiological features of PSA-related sciatic neuropathy are unreported. This case emphasizes the possibility of including PSA within the differential diagnosis of sciatic pain, particularly when conventional aetiologies have been excluded. Recognition of this vascular anomaly is essential for accurate diagnosis and appropriate management, as surgical intervention does not uniformly result in symptoms resolution.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"31 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-01-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145998453","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Genetic and Clinical Spectrum of Hereditary Transthyretin Amyloidosis in Brazil 巴西遗传性甲状腺转蛋白淀粉样变性的遗传和临床谱。

IF 3.2 3区医学 Q1 CLINICAL NEUROLOGY

Journal of the Peripheral Nervous System

Pub Date : 2026-01-07 DOI: 10.1111/jns.70097

Gustavo Maximiano-Alves, Carolina Lavigne-Moreira, Marcus Vinicius Simões, Adilson Junior Pinto Galvão, Flavio Henrique Valicelli, Fernando Saraiva Coneglian, Elisa Vegezzi, Pedro Manoel Marques Garibaldi, Pedro José Tomaselli, Andrea Cortese, Wilson Marques Jr

Background

Transthyretin hereditary amyloidosis (ATTRv) clinical variability has been widely reported, not only across countries and variants but also among families and distinct regions within a single nation. One of the principal challenges in disease management is the accurate determination of age of onset (AOO), which is heterogeneous and has therapeutic implications given the availability of disease-modifying treatments.

Methods

This study characterizes the genetic landscape and clinical onset spectrum of ATTRv in an admixed Brazilian cohort of 175 patients.

Results

Seven TTR pathogenic variants (p.Val50Met, p.Val142Ile, p.Ile127Val, p.Ile88Leu, p.Ala39Asp, p.Phe84Leu, p.Tyr98Phe) were identified. The most common was p.Val50Met (58.8%), followed by p.Val142Ile (29.7%) and p.Ile127Val (7.4%). Notably, 44% of V122I had a neurological onset. Close clinical monitoring of presymptomatic carriers reduced age at diagnosis by 10.5 years. The median AOO was 50 years, with V30M patients presenting earlier (38.5 years) than V122I (p.Val142Ile) (60y) and I107V (p.Ile127Val) (60 years). Familial cases showed a 20.5-year earlier AOO than sporadic cases. In Brazil, late-onset (> 50 years) V30M is more common than previously reported (37.5%); ethnicity can influence AOO within the same variant, and for the first time, we show a distinct geographic pattern: early-onset V30M is more frequent in São Paulo/South, whereas late-onset V30M predominates in the central region.

Interpretation

This study emphasizes the heterogeneity of ATTRv presentation in admixed populations and underscores the need for expanded screening and multicenter studies to refine genotype–phenotypic correlations.

背景：甲状腺素遗传性淀粉样变性（ATTRv）的临床变异性已被广泛报道，不仅在国家和变异之间，而且在一个国家的家庭和不同地区之间。疾病管理的主要挑战之一是准确确定发病年龄（AOO），这是异质的，鉴于疾病改善治疗的可用性，具有治疗意义。方法：本研究在175名巴西混合队列患者中描述了ATTRv的遗传景观和临床发病谱。结果：共鉴定出7个TTR致病变异体（p.Val50Met、p.Val142Ile、p.Ile127Val、p.Ile88Leu、p.Ala39Asp、p.Phe84Leu、p.Tyr98Phe）。最常见的是p.Val50Met(58.8%)，其次是p.Val142Ile（29.7%）和p.Ile127Val（7.4%）。值得注意的是，44%的V122I患者有神经系统疾病。对症状前携带者进行密切的临床监测，可使诊断年龄降低10.5岁。中位AOO为50年，V30M患者比V122I (p.Val142Ile)（60年）和I107V (p.Ile127Val)（60年）更早出现（38.5年）。家族性病例的AOO比散发病例早20.5年。在巴西，晚发性（50岁以下）V30M比之前报道的更为常见（37.5%）；种族可以影响同一变异中的AOO，并且我们首次显示出明显的地理模式：早发性V30M在圣保罗/南部地区更为常见，而晚发性V30M在中部地区占主导地位。解释：该研究强调了混合人群中ATTRv表现的异质性，并强调了扩大筛查和多中心研究以完善基因型-表型相关性的必要性。

{"title":"Genetic and Clinical Spectrum of Hereditary Transthyretin Amyloidosis in Brazil","authors":"Gustavo Maximiano-Alves, Carolina Lavigne-Moreira, Marcus Vinicius Simões, Adilson Junior Pinto Galvão, Flavio Henrique Valicelli, Fernando Saraiva Coneglian, Elisa Vegezzi, Pedro Manoel Marques Garibaldi, Pedro José Tomaselli, Andrea Cortese, Wilson Marques Jr","doi":"10.1111/jns.70097","DOIUrl":"10.1111/jns.70097","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Transthyretin hereditary amyloidosis (ATTRv) clinical variability has been widely reported, not only across countries and variants but also among families and distinct regions within a single nation. One of the principal challenges in disease management is the accurate determination of age of onset (AOO), which is heterogeneous and has therapeutic implications given the availability of disease-modifying treatments.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This study characterizes the genetic landscape and clinical onset spectrum of ATTRv in an admixed Brazilian cohort of 175 patients.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Seven <i>TTR</i> pathogenic variants (p.Val50Met, p.Val142Ile, p.Ile127Val, p.Ile88Leu, p.Ala39Asp, p.Phe84Leu, p.Tyr98Phe) were identified. The most common was p.Val50Met (58.8%), followed by p.Val142Ile (29.7%) and p.Ile127Val (7.4%). Notably, 44% of V122I had a neurological onset. Close clinical monitoring of presymptomatic carriers reduced age at diagnosis by 10.5 years. The median AOO was 50 years, with V30M patients presenting earlier (38.5 years) than V122I (p.Val142Ile) (60y) and I107V (p.Ile127Val) (60 years). Familial cases showed a 20.5-year earlier AOO than sporadic cases. In Brazil, late-onset (> 50 years) V30M is more common than previously reported (37.5%); ethnicity can influence AOO within the same variant, and for the first time, we show a distinct geographic pattern: early-onset V30M is more frequent in São Paulo/South, whereas late-onset V30M predominates in the central region.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>This study emphasizes the heterogeneity of ATTRv presentation in admixed populations and underscores the need for expanded screening and multicenter studies to refine genotype–phenotypic correlations.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"31 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12777902/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145911664","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Evaluation of Nicotinamide Riboside in Prevention of Small Nerve Fiber Axon Degeneration and Promotion of Nerve Regeneration 烟酰胺核苷预防神经小纤维轴突变性和促进神经再生的作用。

IF 3.2 3区医学 Q1 CLINICAL NEUROLOGY

Journal of the Peripheral Nervous System

Pub Date : 2026-01-07 DOI: 10.1111/jns.70101

Simone Thomas, Remi Ben-Davies, Aysel Cetinkaya-Fisgin, Xindan Hu, Xiaoling Li, Sarah Stewart, Baohan Pan, Jeffery L. Twiss, Rajiv R. Ratan, Dianna Willis, Michael Polydefkis, Ahmet Höke

Background and Aims

Recent preclinical studies have shown that nicotinamide adenine dinucleotide (NAD⁺) plays a critical role in molecular mechanisms of axon degeneration, and reductions in NAD⁺ levels are associated with axonal degeneration. Nicotinamide riboside (NR) is a safe and widely available pyridine-nucleoside form of vitamin B3 and is an NAD⁺ precursor.

Methods

To investigate if oral supplementation of synthetic NR can act as a therapeutic agent to prevent degeneration of small somatic sensory axons innervating the skin or promote regeneration of these same fibers in humans, we utilized a validated experimental model of cutaneous nerve degeneration and regeneration and conducted a placebo-controlled, double-blinded Phase 2 study.

Results

NR supplementation did not result in elevation of plasma NAD⁺ levels but resulted in a small increase in NAD⁺ in the skin samples. NR supplementation did not prevent capsaicin-induced degeneration of the epidermal sensory nerve fibers, and there was no difference in the amount of epidermal reinnervation at the 90-day visit. Although there was a small but statistically significant increase in the number of epidermal sensory nerve fibers at the 60-day visit, these results are preliminary and will need to be validated in larger studies.

Interpretation

At present oral NR supplementation, at the doses used in this study, cannot be recommended to prevent neuropathy or to improve nerve regeneration.

背景与目的：最近的临床前研究表明，烟酰胺腺嘌呤二核苷酸（NAD+）在轴突变性的分子机制中起着关键作用，NAD+水平的降低与轴突变性有关。烟酰胺核苷（Nicotinamide riboside， NR）是一种安全且广泛存在的维生素B3的吡啶核苷形式，是一种NAD+前体。方法：为了研究口服合成NR是否可以作为一种治疗药物来预防支配皮肤的小体感觉轴突的退化或促进这些纤维的再生，我们利用了一个经过验证的皮神经退化和再生的实验模型，并进行了一项安慰剂对照、双盲的2期研究。结果：NR补充没有导致血浆NAD+水平升高，但导致皮肤样本中NAD+水平小幅升高。补充NR并不能阻止辣椒素诱导的表皮感觉神经纤维变性，在90天的随访中，表皮神经再生的数量也没有差异。虽然在60天的随访中，表皮感觉神经纤维的数量有少量但统计学上显著的增加，但这些结果是初步的，需要在更大规模的研究中得到验证。解释：目前口服NR补充剂，在本研究中使用的剂量，不能被推荐用于预防神经病变或改善神经再生。

{"title":"Evaluation of Nicotinamide Riboside in Prevention of Small Nerve Fiber Axon Degeneration and Promotion of Nerve Regeneration","authors":"Simone Thomas, Remi Ben-Davies, Aysel Cetinkaya-Fisgin, Xindan Hu, Xiaoling Li, Sarah Stewart, Baohan Pan, Jeffery L. Twiss, Rajiv R. Ratan, Dianna Willis, Michael Polydefkis, Ahmet Höke","doi":"10.1111/jns.70101","DOIUrl":"10.1111/jns.70101","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Recent preclinical studies have shown that nicotinamide adenine dinucleotide (NAD<sup>+</sup>) plays a critical role in molecular mechanisms of axon degeneration, and reductions in NAD<sup>+</sup> levels are associated with axonal degeneration. Nicotinamide riboside (NR) is a safe and widely available pyridine-nucleoside form of vitamin B3 and is an NAD<sup>+</sup> precursor.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>To investigate if oral supplementation of synthetic NR can act as a therapeutic agent to prevent degeneration of small somatic sensory axons innervating the skin or promote regeneration of these same fibers in humans, we utilized a validated experimental model of cutaneous nerve degeneration and regeneration and conducted a placebo-controlled, double-blinded Phase 2 study.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>NR supplementation did not result in elevation of plasma NAD<sup>+</sup> levels but resulted in a small increase in NAD<sup>+</sup> in the skin samples. NR supplementation did not prevent capsaicin-induced degeneration of the epidermal sensory nerve fibers, and there was no difference in the amount of epidermal reinnervation at the 90-day visit. Although there was a small but statistically significant increase in the number of epidermal sensory nerve fibers at the 60-day visit, these results are preliminary and will need to be validated in larger studies.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>At present oral NR supplementation, at the doses used in this study, cannot be recommended to prevent neuropathy or to improve nerve regeneration.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"31 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-01-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145916973","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Utility of the “Modified Erasmus GBS Respiratory Insufficiency Score” in Axonal and Demyelinating Guillain–Barré Syndrome “改良Erasmus GBS呼吸功能不全评分”在轴突和脱髓鞘格林-巴勒综合征中的应用。

IF 3.2 3区医学 Q1 CLINICAL NEUROLOGY

Journal of the Peripheral Nervous System

Pub Date : 2026-01-05 DOI: 10.1111/jns.70096

Yukari Sekiguchi, Sonoko Misawa, Marie Morooka, Tomoki Suichi, Yuki Shiko, Kohei Takahashi, Satoshi Kuwabara

Background

The modified Erasmus GBS Respiratory Insufficiency Score (mEGRIS) has been proposed to be a useful tool for predicting the risk of mechanical ventilation (MV) in Guillain–Barré syndrome (GBS), whereas most of the patients included in previous studies had classical demyelinating GBS. This study validated the utility of the mEGRIS in axonal, as well as demyelinating GBS, defined by electrophysiologic criteria in Japan.

Methods

Data from 214 consecutive patients diagnosed with GBS at our institution within 28 days from disease onset between 1998 and 2023 were reviewed and 200 patients with adequate data were analyzed. Acute motor axonal neuropathy (AMAN) and acute inflammatory demyelinating polyneuropathy (AIDP) were diagnosed by sequential nerve conduction studies and mEGRIS was applied to each group.

Results

A total of 200 GBS patients were classified as AMAN (n = 73 [37%]), AIDP (n = 72 [36%]), or unclassified (n = 55 [28%]) and 27 (14%) patients required MV (18% of AMAN, 15% of AIDP). Patients with MV had a significantly higher mEGRIS than those without MV (17 [median range: 5–29] vs. 6 [0–22]). Approximately 81% of the patients in the moderate- or high-risk group (mEGRIS ≧ 18) required MV. Area under the curves (AUCs) of the mEGRIS prediction formulas was 0.89 (95% CI, 0.82–0.96) for total GBS group and 0.92 (95% CI, 0.85–1.00) for the AMAN group.

Interpretation

The mEGRIS is useful for predicting MV risk in patients with AMAN, as well as AIDP. Close monitoring was required for patients who were classified as moderate or high-risk by mEGRIS, irrespective of GBS subtypes.

背景：改进的Erasmus GBS呼吸功能不全评分（mEGRIS）被认为是预测格林-巴- 综合征（GBS）机械通气（MV）风险的有用工具，而先前研究中的大多数患者为典型脱髓鞘性GBS。这项研究证实了mEGRIS在轴突性和脱髓鞘性GBS（日本电生理标准定义）中的应用。方法：对1998年至2023年间在我院连续诊断为GBS的214例患者的资料进行回顾，并对200例资料充分的患者进行分析。通过序贯神经传导检查诊断急性运动轴索神经病（AMAN）和急性炎症性脱髓鞘多神经病变（AIDP），并应用mEGRIS进行观察。结果：共有200例GBS患者被分类为AMAN （n = 73[37%]）、AIDP （n = 72[36%]）或未分类（n = 55[28%]）， 27例（14%）患者需要MV（18%的AMAN， 15%的AIDP）。MV患者的mEGRIS显著高于无MV患者（17[中位范围：5-29]对6[0-22]）。中高危组（mEGRIS≧18）中约81%的患者需要MV。mEGRIS预测公式的曲线下面积（auc）在总GBS组为0.89 (95% CI, 0.82-0.96)， AMAN组为0.92 （95% CI, 0.85-1.00）。解释：mEGRIS可用于预测AMAN和AIDP患者的MV风险。对于mEGRIS分类为中度或高危的患者，无论GBS亚型如何，都需要密切监测。

{"title":"Utility of the “Modified Erasmus GBS Respiratory Insufficiency Score” in Axonal and Demyelinating Guillain–Barré Syndrome","authors":"Yukari Sekiguchi, Sonoko Misawa, Marie Morooka, Tomoki Suichi, Yuki Shiko, Kohei Takahashi, Satoshi Kuwabara","doi":"10.1111/jns.70096","DOIUrl":"10.1111/jns.70096","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>The modified Erasmus GBS Respiratory Insufficiency Score (mEGRIS) has been proposed to be a useful tool for predicting the risk of mechanical ventilation (MV) in Guillain–Barré syndrome (GBS), whereas most of the patients included in previous studies had classical demyelinating GBS. This study validated the utility of the mEGRIS in axonal, as well as demyelinating GBS, defined by electrophysiologic criteria in Japan.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Data from 214 consecutive patients diagnosed with GBS at our institution within 28 days from disease onset between 1998 and 2023 were reviewed and 200 patients with adequate data were analyzed. Acute motor axonal neuropathy (AMAN) and acute inflammatory demyelinating polyneuropathy (AIDP) were diagnosed by sequential nerve conduction studies and mEGRIS was applied to each group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>A total of 200 GBS patients were classified as AMAN (<i>n</i> = 73 [37%]), AIDP (<i>n</i> = 72 [36%]), or unclassified (<i>n</i> = 55 [28%]) and 27 (14%) patients required MV (18% of AMAN, 15% of AIDP). Patients with MV had a significantly higher mEGRIS than those without MV (17 [median range: 5–29] vs. 6 [0–22]). Approximately 81% of the patients in the moderate- or high-risk group (mEGRIS ≧ 18) required MV. Area under the curves (AUCs) of the mEGRIS prediction formulas was 0.89 (95% CI, 0.82–0.96) for total GBS group and 0.92 (95% CI, 0.85–1.00) for the AMAN group.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>The mEGRIS is useful for predicting MV risk in patients with AMAN, as well as AIDP. Close monitoring was required for patients who were classified as moderate or high-risk by mEGRIS, irrespective of GBS subtypes.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"31 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145906216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Patient Outcomes Among Medicare Beneficiaries With Guillain–Barré Syndrome 格林-巴罗综合征医疗保险受益人的患者结局。

IF 3.2 3区医学 Q1 CLINICAL NEUROLOGY

Journal of the Peripheral Nervous System

Pub Date : 2025-12-29 DOI: 10.1111/jns.70094

Brad Wright, Samantha R. Eiffert, Abagail Cirincione, Joshua Nardin, James F. Howard Jr, Rebecca E. Traub

Background and Aims

Understanding of population-level outcomes for patients with Guillain–Barré syndrome (GBS) remains limited. We identified which GBS patients are most likely to experience worse outcomes using the largest and most current GBS cohort in the United States.

Methods

This retrospective cohort study used 2005–2020 fee-for-service Medicare claims to identify individuals newly diagnosed with GBS (N = 16 280). We used three person-level modified Poisson regressions to estimate hospital and intensive care unit (ICU) lengths of stay and GBS episode length as a function of sociodemographic characteristics, comorbid conditions, and year of diagnosis. We also documented hospital-acquired pressure ulcers and deep vein thromboses as quality indicators.

Results

Median hospital length of stay was 9 days [IQR: 6–18 days] and median GBS episode length was 26 days [IQR: 10–60 days]. Approximately 43% of patients spent time in the ICU, with most of those stays (57%) lasting ≤ 1 week. On average, stays and episodes were significantly longer for men, those with a disability, and those diagnosed with an impulse control disorder, other nervous system diagnoses, or certain cancers, but significantly shorter for Black individuals and those dually eligible for Medicare and Medicaid. Most patients avoided developing pressure ulcers (96%) or deep vein thromboses (91%).

Interpretation

The GBS disease course varies significantly among Medicare enrollees. We identified some factors associated with worse GBS outcomes and others suggesting structural barriers to care. Our findings can improve care delivery by helping clinicians identify high-risk patients, facilitate early interventions, and reduce morbidity and mortality.

背景和目的：对格林-巴利综合征（GBS）患者人群水平结局的了解仍然有限。我们使用美国最大和最新的GBS队列来确定哪些GBS患者最有可能经历更糟糕的结果。方法：本回顾性队列研究使用2005-2020年按服务收费的医疗保险索赔来确定新诊断为GBS的个体（N = 16 280）。我们使用三个人水平的修正泊松回归来估计医院和重症监护病房（ICU）的住院时间和GBS发作时间作为社会人口学特征、合并症和诊断年份的函数。我们还记录了医院获得性压疮和深静脉血栓形成作为质量指标。结果：中位住院时间为9天[IQR: 6-18天]，中位GBS发作时间为26天[IQR: 10-60天]。大约43%的患者在ICU住院，其中大多数（57%）的住院时间≤1周。平均而言，男性、残疾人、被诊断为冲动控制障碍、其他神经系统诊断或某些癌症的人的住院时间和发作时间明显更长，但黑人和双重符合医疗保险和医疗补助资格的人的住院时间和发作时间明显更短。大多数患者避免发生压疮（96%）或深静脉血栓（91%）。解释：GBS病程在医保参保者中差异显著。我们确定了一些与更糟糕的GBS结果相关的因素，以及其他表明护理结构性障碍的因素。我们的研究结果可以帮助临床医生识别高危患者，促进早期干预，降低发病率和死亡率，从而改善护理服务。

{"title":"Patient Outcomes Among Medicare Beneficiaries With Guillain–Barré Syndrome","authors":"Brad Wright, Samantha R. Eiffert, Abagail Cirincione, Joshua Nardin, James F. Howard Jr, Rebecca E. Traub","doi":"10.1111/jns.70094","DOIUrl":"10.1111/jns.70094","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Understanding of population-level outcomes for patients with Guillain–Barré syndrome (GBS) remains limited. We identified which GBS patients are most likely to experience worse outcomes using the largest and most current GBS cohort in the United States.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>This retrospective cohort study used 2005–2020 fee-for-service Medicare claims to identify individuals newly diagnosed with GBS (<i>N</i> = 16 280). We used three person-level modified Poisson regressions to estimate hospital and intensive care unit (ICU) lengths of stay and GBS episode length as a function of sociodemographic characteristics, comorbid conditions, and year of diagnosis. We also documented hospital-acquired pressure ulcers and deep vein thromboses as quality indicators.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Median hospital length of stay was 9 days [IQR: 6–18 days] and median GBS episode length was 26 days [IQR: 10–60 days]. Approximately 43% of patients spent time in the ICU, with most of those stays (57%) lasting ≤ 1 week. On average, stays and episodes were significantly longer for men, those with a disability, and those diagnosed with an impulse control disorder, other nervous system diagnoses, or certain cancers, but significantly shorter for Black individuals and those dually eligible for Medicare and Medicaid. Most patients avoided developing pressure ulcers (96%) or deep vein thromboses (91%).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>The GBS disease course varies significantly among Medicare enrollees. We identified some factors associated with worse GBS outcomes and others suggesting structural barriers to care. Our findings can improve care delivery by helping clinicians identify high-risk patients, facilitate early interventions, and reduce morbidity and mortality.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"31 1","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-12-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12748927/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145856773","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Prospective Evaluation of Machine-Assisted Electrophysiologic and Online Clinical Diagnostic Support Tools in Chronic Inflammatory Demyelinating Polyradiculoneuropathy 慢性炎症性脱髓鞘性多根神经病变的机器辅助电生理和在线临床诊断支持工具的前瞻性评价。

IF 3.2 3区医学 Q1 CLINICAL NEUROLOGY

Journal of the Peripheral Nervous System

Pub Date : 2025-12-18 DOI: 10.1111/jns.70084

Michael P. Skolka, Grace Swart, Shahar Shelly, Thapat Wannarong, Stefan Stålberg, Benjamin Stålberg, Abe Gardner, Jacob Price, Ruple S. Laughlin, Divyanshu Dubey, John R. Mills, Jay Mandrekar, Christopher J. Klein

Background and Aims

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a common, treatable, autoimmune, neuropathy frequently misdiagnosed. The complex electrodiagnostic (EDX) criteria required for diagnosis are challenging to apply in routine practice. This study evaluates the effectiveness of a machine-assisted EDX tool in real-time identification of demyelinating nerve conduction studies (NCS) stipulated by 2021-EAN/PNS CIDP criteria in conjunction with an online CIDP clinical probability calculator.

Methods

We prospectively evaluated 100 consecutive patients with referral or EDX diagnosis of polyradiculoneuropathy beginning January 1, 2024. Fifty patients were included, each from Jacksonville and Rochester Mayo Clinics. Routine electromyography (EMG) reports were compared to a machine-assisted support tool applying 2021-EAN/PNS CIDP EDX criteria to NCS assessing demyelination. The EDX-assistant performance was compared to the final clinical diagnosis and our previously reported online CIDP clinical prediction tool (https://news.mayocliniclabs.com/cidp-calculator/).

Results

Among 100 patients (60% male; median age 64), 30 had a final clinical CIDP diagnosis with 29 having intravenous immunoglobulin follow-up; 27 (93%) improved and 2 (7%) stabilized. Routine EMGs reported demyelination in 14 of 30 (47%), with 46% sensitivity and 79% specificity. The EDX-assistant identified CIDP demyelination in 28 of 30 (93%), with 93% sensitivity and 57% specificity. The clinical calculator detected CIDP in 30 of 30 (100%) with 86% specificity, increasing to 94% after excluding false positives lacking demyelinating features on the EDX tool.

Interpretation

A real-time machine-assisted EDX support tool, used with a clinical web-based calculator, streamlines CIDP assessment by improving standardized identification of 2021-EAN/PNS CIDP demyelinating NCS criteria and aiding clinical decisions.

背景和目的：慢性炎症性脱髓鞘性多根神经病变（CIDP）是一种常见的、可治疗的自身免疫性神经病变，常被误诊。诊断所需的复杂电诊断（EDX）标准在常规实践中应用具有挑战性。本研究评估了机器辅助EDX工具在2021-EAN/PNS CIDP标准规定的脱髓鞘神经传导研究（NCS）实时识别中的有效性，并结合在线CIDP临床概率计算器。方法：从2024年1月1日开始，我们前瞻性评估了100例转诊或EDX诊断为多神经根神经病变的连续患者。50名患者分别来自杰克逊维尔和罗切斯特梅奥诊所。将常规肌电图（EMG）报告与机器辅助支持工具进行比较，该工具应用2021-EAN/PNS CIDP EDX标准评估NCS脱髓鞘。将EDX-assistant的表现与最终临床诊断和我们之前报道的在线CIDP临床预测工具（https://news.mayocliniclabs.com/cidp-calculator/）.Results)进行比较：在100例患者中（60%为男性，中位年龄64岁），30例最终临床CIDP诊断，29例进行静脉免疫球蛋白随访；27例（93%）好转，2例（7%）稳定。常规肌电图显示30例中有14例（47%）脱髓鞘，敏感性46%，特异性79%。EDX-assistant在30例中有28例（93%）诊断出CIDP脱髓鞘，灵敏度为93%，特异性为57%。临床计算器在30例（100%）中检测出CIDP，特异性为86%，在排除EDX工具上缺乏脱髓鞘特征的假阳性后，特异性增加到94%。解释：实时机器辅助EDX支持工具与临床基于网络的计算器一起使用，通过改进2021-EAN/PNS CIDP脱髓鞘NCS标准的标准化识别并辅助临床决策，简化了CIDP评估。

{"title":"Prospective Evaluation of Machine-Assisted Electrophysiologic and Online Clinical Diagnostic Support Tools in Chronic Inflammatory Demyelinating Polyradiculoneuropathy","authors":"Michael P. Skolka, Grace Swart, Shahar Shelly, Thapat Wannarong, Stefan Stålberg, Benjamin Stålberg, Abe Gardner, Jacob Price, Ruple S. Laughlin, Divyanshu Dubey, John R. Mills, Jay Mandrekar, Christopher J. Klein","doi":"10.1111/jns.70084","DOIUrl":"10.1111/jns.70084","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a common, treatable, autoimmune, neuropathy frequently misdiagnosed. The complex electrodiagnostic (EDX) criteria required for diagnosis are challenging to apply in routine practice. This study evaluates the effectiveness of a machine-assisted EDX tool in real-time identification of demyelinating nerve conduction studies (NCS) stipulated by 2021-EAN/PNS CIDP criteria in conjunction with an online CIDP clinical probability calculator.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>We prospectively evaluated 100 consecutive patients with referral or EDX diagnosis of polyradiculoneuropathy beginning January 1, 2024. Fifty patients were included, each from Jacksonville and Rochester Mayo Clinics. Routine electromyography (EMG) reports were compared to a machine-assisted support tool applying 2021-EAN/PNS CIDP EDX criteria to NCS assessing demyelination. The EDX-assistant performance was compared to the final clinical diagnosis and our previously reported online CIDP clinical prediction tool (https://news.mayocliniclabs.com/cidp-calculator/).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Among 100 patients (60% male; median age 64), 30 had a final clinical CIDP diagnosis with 29 having intravenous immunoglobulin follow-up; 27 (93%) improved and 2 (7%) stabilized. Routine EMGs reported demyelination in 14 of 30 (47%), with 46% sensitivity and 79% specificity. The EDX-assistant identified CIDP demyelination in 28 of 30 (93%), with 93% sensitivity and 57% specificity. The clinical calculator detected CIDP in 30 of 30 (100%) with 86% specificity, increasing to 94% after excluding false positives lacking demyelinating features on the EDX tool.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>A real-time machine-assisted EDX support tool, used with a clinical web-based calculator, streamlines CIDP assessment by improving standardized identification of 2021-EAN/PNS CIDP demyelinating NCS criteria and aiding clinical decisions.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"30 4","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145781638","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Longitudinal Assessment of Quality of Life and Functionality by CAP-PRI in Patients With Active Chronic Inflammatory Demyelinating Polyradiculoneuropathy CAP-PRI对活动性慢性炎症性脱髓鞘性多根神经病变患者的生活质量和功能的纵向评估。

IF 3.2 3区医学 Q1 CLINICAL NEUROLOGY

Journal of the Peripheral Nervous System

Pub Date : 2025-12-18 DOI: 10.1111/jns.70091

Ivo Bozovic, Kelly Gwathmey, Stojan Peric, Aleksandra Kacar, Jelena Lazovic, Reza Sadjadi, Ivana Basta

Background and Aims

In most studies to date, generic health-related quality of life (QoL) questionnaires have been used in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Unfortunately, these tools are often considered insufficient for capturing the unique characteristics of this specific, rare disease. The Chronic Acquired Polyneuropathy Patient-Reported Index (CAP-PRI) is a measure which specifically targets patients with chronic immune-mediated polyneuropathies. This is the first study which longitudinally assessed QoL and functionality by CAP-PRI in patients with active CIDP.

Methods

CAP-PRI testing was conducted at three time points (baseline, year one and year four) in 57 CIDP patients with active disease at baseline. In addition, the Medical Research Council Sum Score (MRC-SS), Inflammatory Neuropathy Cause and Treatment (INCAT) disability score, Inflammatory Rasch-built Overall Disability Scale (I-RODS), and the generic QOL instrument, the Short Form 36 (SF-36) were used in all tested patients at all three time points.

Results

At the baseline and two other time points, CAP-PRI showed strong correlations with impairment (MRC-SS), functionality (INCAT, I-RODS), and the SF-36. At year one and year four, CAP-PRI was able to make a differentiation between patients whose impairment/disability improved compared to patients who deteriorated, and it performed better than SF-36. One- and four-year changes in CAP-PRI correlated with a change in MRC-SS, INCAT, and I-RODS.

Interpretation

CAP-PRI is a highly reliable and sensitive measure for assessing QoL in patients with active CIDP. Its consistent performance over time supports its utility in monitoring CIDP patients with active disease in clinical and research settings.

背景和目的：在迄今为止的大多数研究中，通用的健康相关生活质量（QoL）问卷调查已用于慢性炎症性脱髓鞘性多根神经病变（CIDP）患者。不幸的是，这些工具通常被认为不足以捕捉这种特殊的罕见疾病的独特特征。慢性获得性多神经病变患者报告指数（CAP-PRI）是一种专门针对慢性免疫介导的多神经病变患者的指标。这是第一个通过CAP-PRI对活动性CIDP患者的生活质量和功能进行纵向评估的研究。方法：在三个时间点（基线、第1年和第4年）对57例基线时疾病活动性的CIDP患者进行CAP-PRI测试。此外，医学研究委员会总评分（MRC-SS）、炎症性神经病变病因和治疗（INCAT）残疾评分、炎症性rasch构建的整体残疾量表（I-RODS）和通用的生活质量量表短表36 （SF-36）在所有三个时间点被用于所有被测试的患者。结果：在基线和其他两个时间点，CAP-PRI显示与损伤（MRC-SS）、功能（INCAT, I-RODS）和SF-36有很强的相关性。在第一年和第四年，CAP-PRI能够区分损伤/残疾改善的患者与恶化的患者，并且它比SF-36表现更好。1年和4年CAP-PRI的变化与MRC-SS、INCAT和i - rod的变化相关。CAP-PRI是一种高度可靠和敏感的评估活动性CIDP患者生活质量的方法。随着时间的推移，它的一贯表现支持了它在临床和研究环境中监测患有活动性疾病的CIDP患者的效用。

{"title":"Longitudinal Assessment of Quality of Life and Functionality by CAP-PRI in Patients With Active Chronic Inflammatory Demyelinating Polyradiculoneuropathy","authors":"Ivo Bozovic, Kelly Gwathmey, Stojan Peric, Aleksandra Kacar, Jelena Lazovic, Reza Sadjadi, Ivana Basta","doi":"10.1111/jns.70091","DOIUrl":"10.1111/jns.70091","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>In most studies to date, generic health-related quality of life (QoL) questionnaires have been used in patients with chronic inflammatory demyelinating polyradiculoneuropathy (CIDP). Unfortunately, these tools are often considered insufficient for capturing the unique characteristics of this specific, rare disease. The Chronic Acquired Polyneuropathy Patient-Reported Index (CAP-PRI) is a measure which specifically targets patients with chronic immune-mediated polyneuropathies. This is the first study which longitudinally assessed QoL and functionality by CAP-PRI in patients with active CIDP.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>CAP-PRI testing was conducted at three time points (baseline, year one and year four) in 57 CIDP patients with active disease at baseline. In addition, the Medical Research Council Sum Score (MRC-SS), Inflammatory Neuropathy Cause and Treatment (INCAT) disability score, Inflammatory Rasch-built Overall Disability Scale (I-RODS), and the generic QOL instrument, the Short Form 36 (SF-36) were used in all tested patients at all three time points.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>At the baseline and two other time points, CAP-PRI showed strong correlations with impairment (MRC-SS), functionality (INCAT, I-RODS), and the SF-36. At year one and year four, CAP-PRI was able to make a differentiation between patients whose impairment/disability improved compared to patients who deteriorated, and it performed better than SF-36. One- and four-year changes in CAP-PRI correlated with a change in MRC-SS, INCAT, and I-RODS.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>CAP-PRI is a highly reliable and sensitive measure for assessing QoL in patients with active CIDP. Its consistent performance over time supports its utility in monitoring CIDP patients with active disease in clinical and research settings.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"30 4","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145774840","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Impact of High-Dose Tafamidis on Hereditary ATTR (ATTRv) Amyloidosis With Central Nervous System Involvement: Two Case Reports With Clinical, Radiological and Cerebrospinal Fluid Follow Up 高剂量他法非地对遗传性ATTR （ATTRv）淀粉样变性伴中枢神经系统的影响：2例临床、影像学和脑脊液随访报告

IF 3.2 3区医学 Q1 CLINICAL NEUROLOGY

Journal of the Peripheral Nervous System

Pub Date : 2025-12-11 DOI: 10.1111/jns.70088

Victor Jia Wei Zhang, Laura Mantoan Ritter, Chandrashekar Hoskote, Ata Siddiqui, Michael Lunn, Julian Gillmore, Mary M. Reilly

Background

Treatment options for central nervous system (CNS) manifestations of ATTRv amyloidosis remain limited, with no disease-modifying therapy. However, previous case series have indicated that tafamidis (a transthyretin stabiliser) crosses the blood–brain barrier in small quantities. We present long-term follow-up data on two patients with CNS manifestations of ATTRv who received high-dose (61 mg) oral tafamidis.

Methods

Patient one is a 48-year-old man with p.Gly73Ala ATTRv peripheral neuropathy and commenced on gene-silencing therapy. He was subsequently diagnosed with early ATTRv CNS involvement, prompting the addition of tafamidis since age 45. Patient two is a 27-year-old woman with p.Gly67Arg ATTRv with significant CNS involvement resulting in epilepsy and encephalopathy. Since age 21, she has been on gene-silencing therapy and tafamidis.

Results

Following 3 years of therapy, patient one has remained clinically asymptomatic. However, brain magnetic resonance imaging (MRI) and cerebrospinal fluid assessment have demonstrated progression of his CNS ATTRv. Followed 6 years of therapy, patient two has continued to have seizures requiring escalation of anti-seizure medications and MRI brain has shown progression of CNS disease.

Conclusions

In our two patients, progression of CNS disease occurred whilst on high-dose tafamidis, highlighting the importance of further studies into the monitoring and treatment of CNS manifestations of ATTRv.

背景：ATTRv淀粉样变的中枢神经系统（CNS）表现的治疗选择仍然有限，没有疾病改善治疗。然而，先前的病例系列表明，他法底斯（一种甲状腺素转运稳定剂）穿过血脑屏障的量很小。我们对两名接受高剂量（61 mg）口服他法非地的有中枢神经系统表现的ATTRv患者进行了长期随访。方法患者1为48岁男性p.Gly73Ala ATTRv周围神经病变患者，开始接受基因沉默治疗。随后，他被诊断为早期ATTRv中枢神经系统受累，促使他在45岁时增加了他法底肌。患者2为一名27岁女性，患有p.Gly67Arg ATTRv，伴有明显的中枢神经系统受累，导致癫痫和脑病。从21岁开始，她就一直在接受基因沉默疗法和塔法米底疗法。结果经3年治疗，患者1无临床症状。然而，脑磁共振成像（MRI）和脑脊液评估显示他的中枢神经系统ATTRv进展。经过6年的治疗，患者2持续出现癫痫发作，需要增加抗癫痫药物治疗，MRI显示中枢神经系统疾病进展。在我们的两例患者中，高剂量他法非底斯治疗期间发生了中枢神经系统疾病的进展，这突出了进一步研究ATTRv中枢神经系统表现的监测和治疗的重要性。

{"title":"Impact of High-Dose Tafamidis on Hereditary ATTR (ATTRv) Amyloidosis With Central Nervous System Involvement: Two Case Reports With Clinical, Radiological and Cerebrospinal Fluid Follow Up","authors":"Victor Jia Wei Zhang, Laura Mantoan Ritter, Chandrashekar Hoskote, Ata Siddiqui, Michael Lunn, Julian Gillmore, Mary M. Reilly","doi":"10.1111/jns.70088","DOIUrl":"https://doi.org/10.1111/jns.70088","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background</h3>\u0000 \u0000 <p>Treatment options for central nervous system (CNS) manifestations of ATTRv amyloidosis remain limited, with no disease-modifying therapy. However, previous case series have indicated that tafamidis (a transthyretin stabiliser) crosses the blood–brain barrier in small quantities. We present long-term follow-up data on two patients with CNS manifestations of ATTRv who received high-dose (61 mg) oral tafamidis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Patient one is a 48-year-old man with p.Gly73Ala ATTRv peripheral neuropathy and commenced on gene-silencing therapy. He was subsequently diagnosed with early ATTRv CNS involvement, prompting the addition of tafamidis since age 45. Patient two is a 27-year-old woman with p.Gly67Arg ATTRv with significant CNS involvement resulting in epilepsy and encephalopathy. Since age 21, she has been on gene-silencing therapy and tafamidis.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Following 3 years of therapy, patient one has remained clinically asymptomatic. However, brain magnetic resonance imaging (MRI) and cerebrospinal fluid assessment have demonstrated progression of his CNS ATTRv. Followed 6 years of therapy, patient two has continued to have seizures requiring escalation of anti-seizure medications and MRI brain has shown progression of CNS disease.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusions</h3>\u0000 \u0000 <p>In our two patients, progression of CNS disease occurred whilst on high-dose tafamidis, highlighting the importance of further studies into the monitoring and treatment of CNS manifestations of ATTRv.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"30 4","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145739641","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Blood 1-Deoxysphingolipid Levels Are Associated With Epidermal Denervation in Small Fiber Neuropathy 血1-脱氧鞘脂水平与小纤维神经病表皮失神经支配有关。

IF 3.2 3区医学 Q1 CLINICAL NEUROLOGY

Journal of the Peripheral Nervous System

Pub Date : 2025-12-11 DOI: 10.1111/jns.70089

Luisa Kreß, Caren Meyer zu Altenschildesche, Nadine Egenolf, Claudia Sommer, Thorsten Hornemann, Nurcan Üçeyler

Background and Aims

Dysfunctional sphingolipid metabolism leads to nerve fiber degeneration, particularly of small caliber Aδ and C fibers, in hereditary sensory and autonomic neuropathies. We aimed to investigate the association of blood 1-deoxysphingolipid (1-deoxySL) profiles and skin denervation in idiopathic small fiber neuropathy (SFN).

Methods

Seventy-five patients with idiopathic SFN were recruited prospectively. Patients underwent a skin punch biopsy at the lower leg and upper thigh for intraepidermal nerve fiber density (IENFD) quantification. IENFD was correlated with individual blood 1-deoxySL levels, amino acid profiles, and determinants of glucose and lipoprotein metabolism.

Results

Median distal IENFD in SFN patients was 5.3 fibers/mm. In 38/75 (51%) patients, IENFD was ≤ 5.3 fibers/mm (i.e., “low fiber density,” LFD), while in 37/75 (49%) patients, IENFD was > 5.3 fibers/mm (i.e., “high fiber density,” HFD). 1-deoxySL was higher in patients with LFD compared to HFD (p < 0.05). Fasting plasma glucose was also higher in patients with LFD than in patients with HFD (p < 0.01), while HDL was lower in patients with LFD compared to HFD (p < 0.001).

Interpretation

1-deoxySL, lipoprotein metabolism, and glucose levels are associated with the extent of epidermal denervation in SFN, supporting the role of this metabolic axis in small nerve fiber pathology.

背景和目的：在遗传性感觉和自主神经病变中，鞘脂代谢功能障碍导致神经纤维变性，特别是小口径Aδ和C纤维变性。我们旨在研究特发性小纤维神经病（SFN）患者血液1-脱氧鞘脂（1-deoxySL）谱与皮肤去神经支配的关系。方法：前瞻性招募75例特发性SFN患者。患者在小腿和大腿上部进行皮肤穿刺活检，以量化表皮内神经纤维密度（IENFD）。IENFD与个体血液1-脱氧ysl水平、氨基酸谱以及葡萄糖和脂蛋白代谢的决定因素相关。结果：SFN患者中位远端IENFD为5.3纤维/mm。在38/75（51%）的患者中，IENFD≤5.3纤维/mm（即“低纤维密度”LFD），而在37/75（49%）的患者中，IENFD为bb0 5.3纤维/mm（即“高纤维密度”HFD）。解释：1-deoxySL、脂蛋白代谢和葡萄糖水平与SFN中表皮失神经支配的程度相关，支持该代谢轴在小神经纤维病理中的作用。

{"title":"Blood 1-Deoxysphingolipid Levels Are Associated With Epidermal Denervation in Small Fiber Neuropathy","authors":"Luisa Kreß, Caren Meyer zu Altenschildesche, Nadine Egenolf, Claudia Sommer, Thorsten Hornemann, Nurcan Üçeyler","doi":"10.1111/jns.70089","DOIUrl":"10.1111/jns.70089","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Background and Aims</h3>\u0000 \u0000 <p>Dysfunctional sphingolipid metabolism leads to nerve fiber degeneration, particularly of small caliber Aδ and C fibers, in hereditary sensory and autonomic neuropathies. We aimed to investigate the association of blood 1-deoxysphingolipid (1-deoxySL) profiles and skin denervation in idiopathic small fiber neuropathy (SFN).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 <p>Seventy-five patients with idiopathic SFN were recruited prospectively. Patients underwent a skin punch biopsy at the lower leg and upper thigh for intraepidermal nerve fiber density (IENFD) quantification. IENFD was correlated with individual blood 1-deoxySL levels, amino acid profiles, and determinants of glucose and lipoprotein metabolism.</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 <p>Median distal IENFD in SFN patients was 5.3 fibers/mm. In 38/75 (51%) patients, IENFD was ≤ 5.3 fibers/mm (i.e., “low fiber density,” LFD), while in 37/75 (49%) patients, IENFD was > 5.3 fibers/mm (i.e., “high fiber density,” HFD). 1-deoxySL was higher in patients with LFD compared to HFD (<i>p</i> < 0.05). Fasting plasma glucose was also higher in patients with LFD than in patients with HFD (<i>p</i> < 0.01), while HDL was lower in patients with LFD compared to HFD (<i>p</i> < 0.001).</p>\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Interpretation</h3>\u0000 \u0000 <p>1-deoxySL, lipoprotein metabolism, and glucose levels are associated with the extent of epidermal denervation in SFN, supporting the role of this metabolic axis in small nerve fiber pathology.</p>\u0000 </section>\u0000 </div>","PeriodicalId":17451,"journal":{"name":"Journal of the Peripheral Nervous System","volume":"30 4","pages":""},"PeriodicalIF":3.2,"publicationDate":"2025-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/jns.70089","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145723998","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0